文献速递肝病消化道肿瘤与早癌

亚洲与中东和北非地区非酒精性脂肪性肝病相关肝并发症负担:全球疾病负担2009-2019数据

Burden of non-alcoholic fatty liver disease in Asia, the Middle East and North Africa: Data from Global Burden of Disease 2009-2019.
PubMed 文献 · J Hepatol · 2021-05-31

本研究利用全球疾病负担数据评估2009-2019年亚洲及中东和北非地区非酒精性脂肪性肝病相关肝并发症(肝硬化和肝癌)的发病率、死亡率和伤残调整生命年。2019年全球非酒精性脂肪性肝病相关肝并发症发病17万例,占所有慢性肝病相关肝并发症发病的6.6%;死亡168969例,占8.6%。亚洲占全球发病的48.3%和死亡的46.2%,中东和北非分别占8.9%和8.6%。2009-2019年亚洲和中东和北非地区非酒精性脂肪性肝病相关伤残调整生命年上升,且与膳食、代谢、低体力活动和烟草使用等因素相关。

要点

  • 2019年全球非酒精性脂肪性肝病相关肝并发症发病17万例,占所有慢性肝病相关肝并发症的6.6%。
  • 亚洲占全球非酒精性脂肪性肝病相关肝并发症发病的48.3%和死亡的46.2%。
  • 2009-2019年亚洲和中东和北非地区非酒精性脂肪性肝病相关伤残调整生命年上升,风险因素包括膳食、代谢、低体力活动和烟草使用。

核心结论

  • 非酒精性脂肪性肝病在亚洲和中东和北非地区造成沉重负担,约占全球非酒精性脂肪性肝病相关肝并发症负担的一半。

研究设计与样本

  • 基于全球疾病负担数据,评估2009-2019年亚洲和中东和北非地区非酒精性脂肪性肝病相关肝并发症的发病率、死亡率和伤残调整生命年,使用连接点回归模型计算年度变化百分比,采用偏斯皮尔曼相关系数分析其与低体力活动、膳食和代谢风险因素的关联。

主要发现

  • 2019年全球非酒精性脂肪性肝病相关肝并发症发病17万例,占所有慢性肝病相关肝并发症发病的6.6%;死亡168969例,占8.6%。
  • 亚洲占全球非酒精性脂肪性肝病相关肝并发症发病的48.3%和死亡的46.2%;中东和北非分别占8.9%和8.6%。
  • 2009-2019年亚洲和中东和北非地区非酒精性脂肪性肝病相关伤残调整生命年上升,从南亚(年度变化百分比=+2.12% vs. -0.94%)到高收入亚太地区(年度变化百分比=-0.07%,p=0.646 vs. -0.97%)。
  • 亚洲非酒精性脂肪性肝病相关伤残调整生命年与膳食风险(95%CI 0.280-0.763,p=0.004)、代谢风险(0.341-0.790,p<0.001)和烟草使用(0.134-0.691,p=0.007)显著相关;中东和北非与低体力活动(0.557-0.918,p<0.001)、代谢风险(0.432-0.888,p=0.001)和膳食风险(0.315-0.855,p=0.001)相关。

临床怎么用

  • 消化内科医生应关注亚洲和中东和北非地区非酒精性脂肪性肝病相关肝并发症负担的上升趋势,针对膳食、代谢、低体力活动和烟草使用等可干预风险因素进行患者教育和管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIM: Non-alcoholic fatty liver disease (NAFLD) has become a major cause of chronic liver disease (CLD) worldwide. Our aim was to assess the burden of liver complications (LC, cirrhosis and liver cancer) related to NAFLD (LC-NAFLD) between 2009-2019 in Asia and the Middle East and North Africa (MENA) region. METHODS: We used Global Burden of Disease data to assess incidence, mortality, and disability-adjusted life years (DALYs) for LC-NAFLD from Asia and the MENA region. Annual % change (APC) in rates were computed using a joinpoint regression model. Associations of LC-NAFLD with low physical activity, diet and metabolic risks were determined by partial Spearman correlation coefficients (ρ). RESULTS: Globally in 2019, there were 170,000 incident cases of LC-NAFLD, accounting for 6.6% of LC incident cases from all CLDs. There were 168,969 deaths related to LC-NAFLD, accounting for 8.6% of LC deaths from all CLDs. Asia accounted for 48.3% of the global incidence of LC-NAFLD and for 46.2% of deaths attributable to LC-NAFLD, while MENA accounted for 8.9% and 8.6%, respectively. There were 2.08 million DALYs in Asia and 340,000 DALYs in MENA. From 2009 to 2019, regions in Asia and MENA experienced a rise in DALYs attributable to LC-NAFLD (compared to LC from other CLDs), ranging from South Asia (APC = +2.12% vs. -0.94%) to high-income Asia Pacific (APC = -0.07%, p = 0.646 vs. -0.97%). In Asia, NAFLD-related DALYs were significantly correlated with dietary risks (95% CI 0.280-0.763, p = 0.004), metabolic risks (0.341-0.790, p <0.001) and tobacco use (0.134-0.691, p = 0.007). In MENA, low physical activity (0.557-0.918, p <0.001), metabolic risks (0.432-0.888, p = 0.001), and dietary risks (0.315-0.855, p = 0.001) correlated with DALYs. CONCLUSIONS: NAFLD is posing a substantial burden in Asia and MENA. About half of the global burden of LC-NAFLD is accounted for by these regions. LAY SUMMARY: Non-alcoholic fatty liver disease (NAFLD) has emerged as one of the most common causes of chronic liver disease worldwide. We used Global Burden of Disease data to assess the incidence, mortality, and disability-adjusted life years attributable to NAFLD-related liver complications in Asia, the Middle East and North Africa. NAFLD is poised to contribute to a substantial liver disease burden in these regions. Regional and global policies are needed to address the increasing burden of complications of NAFLD.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Golabi P, Paik JM, AlQahtani S, et al. Burden of non-alcoholic fatty liver disease in Asia, the Middle East and North Africa: Data from Global Burden of Disease 2009-2019. J Hepatol. 2021. PMID: 34081959. doi:10.1016/j.jhep.2021.05.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。